DXCM Chart

1 Month

	Date	Diff
	2023-03-31	+1.56 %
DexCom (DXCM) saw a 1.56% increase in stock price following the launch of its newest continuous glucose monitoring (CGM) device, the G7, which has received positive initial feedback from users and represents a significant market opportunity given the growing prevalence of diabetes worldwide. Dexcom's stock (DXCM) went up by 1.56% after DKSH Business Unit Healthcare was appointed as the official partner to launch the Dexcom G6 Continuous Glucose Monitoring System in Southeast Asia, which received approval from Singapore's HSA last year and can now be accessed by Singaporeans this month.
	2023-03-29	+0.12 %
DexCom's stock went up due to expectations of increased revenue growth from the launch of its CGM device, the G7, in the US and Europe, its aggressive marketing strategy, and the potential for growth in the CGM market as diabetes affects millions of people worldwide.
	2023-03-24	-0.36 %
DexCom's (DXCM) stock went down by 0.36% last night, and the article discusses the company's return on equity (ROE) to determine if it could be influencing the market and finds that, despite having a respectable ROE and impressive net income growth, the latest industry analyst forecasts predict a slowdown in earnings growth for the company.
	2023-03-23	-0.43 %
Dexcom's (DXCM) stock was down 0.43% last night, despite the company having had a strong 2022 with revenue of $3bn, plus increased adoption of continuous glucose monitoring devices; the factor behind the decline in stock value is unclear.
	2023-03-21	+1.51 %
The article discusses three exceptional growth stocks, including Dexcom (DXCM), which has seen a significant increase in value recently, and could potentially produce a 10x return for patient investors. The reason for the increase in the stock value is not mentioned in the article.
	2023-03-10	-3.85 %
Dexcom (DXCM) stock went down by 3.85% following Oracle's (ORCL) earnings call.
	2023-03-09	-0.59 %
DexCom (DXCM) stock went down by -0.59% due to market fluctuations, however, the company has a significant and still untapped market opportunity as a leading maker of continuous glucose monitoring systems, with 1.7 million people globally currently using its CGM products, and is currently launching its latest product, the G7 CGM as a strong growth catalyst. DarioHealth Corp has reported financial results for the fourth quarter and full year 2022 and provided a corporate and commercial update, with a 58.4% reduction in operating loss in the fourth quarter 2022 as compared to the fourth quarter of 2021, driven by the transition to a business-to-business (B2B) integrated multi-condition platform, however, the reason for Dexcom's (DXCM) stock going down is not mentioned in the article.
	2023-03-07	+0.49 %
DexCom's stock rose by 0.49% on Monday after a previous drop due to rival Abbott Laboratories receiving FDA approval for glucose monitors connected to insulin pumps, adding competition to DexCom's previously monopoly grip on the market. Despite the healthcare sector’s recent bear market, a few healthcare stocks, such as GE Healthcare and Reata Pharmaceuticals, are trading higher, with Reata’s shares up 133% since the start of 2023, partly thanks to FDA approval for its Friedreich’s ataxia drug, Skyclarys. Defying the downward trend, the diabetes device specialist DexCom last night was up 0.49% regarding its stock.
	2023-03-06	-7.87 %
Dexcom (DXCM) stock went down 7.87% as the FDA cleared Abbott Laboratories (ABT) to pair its glucose monitors with automated insulin pumps, making Abbott a competitor in the diabetes market that was previously dominated by Dexcom.
	2023-03-03	+1.39 %
Shares of DexCom (NASDAQ:DXCM) went up by 1.39% last night after the company's three years of annual EPS growth was recorded at 47%, leading to higher investor confidence while its EBIT margins also rose from 11% to 13%. DexCom's stock went up by 1.39% as it has potential for long-term growth, with its continuous glucose monitoring technology aiding diabetes patients to measure glucose levels more frequently and conveniently, despite potential risks such as increased competition from Apple and the company's high valuation. Dexcom's (DXCM) stock went up by 1.39% last night along with the overall stock market rally, despite the 10-year Treasury yield crossing above 4%. The article mentions that Dexcom (DXCM) stock went up by 1.39% last night, but does not provide a specific reason for the increase.
	2023-03-02	+9.46 %
Dexcom's stock went up by 9.46% after Centers for Medicare and Medicaid Services announced their decision to cover continuous glucose monitors for a broader group of type 2 diabetics, which goes into effect in April. Dexcom (DXCM) stock went up by 9.46% due to reports of Apple potentially bringing a glucose monitor to market, which would simplify the process of tracking glucose levels for consumers and could lead to a bigger move into the healthcare industry for the tech giant. DexCom (DXCM) stock went up by 9.46% as the company develops and sells continuous glucose monitoring (CGM) devices, which track blood sugar levels, and has a broad and growing opportunity domestically and internationally as it aims to generate recurring revenue from its existing users while expanding its user base to 1.7 million people, with potential to double its addressable reimbursed market in the United States. Dexcom stock rose almost 9.5% due to Centers for Medicare and Medicaid Services announcing that it would cover continuous glucose monitors for a broader group of type 2 diabetics earlier than predicted, which will impact companies such as Abbott Laboratories that produce devices like FreeStyle Libre.
	2023-02-28	+0.39 %
Israel Englander, Millennium Management chairman and CEO, has increased his stake in medical device maker Dexcom. This is likely indicative of his positive outlook on the company's future.
	2023-02-24	-1.59 %
A stock split does nothing to augment the value of the company, but can make the stock more accessible to the average investor again. The Securities and Exchange Commission and Federal Trade Commission are investigating Abbott in connection with its infant formula business.
	2023-02-23	+0.2 %
Dexcom is working on a top-secret project that will help the company make additional inroads into the healthcare field. Dexcom(DXCM) stock price goes up because it is a leading diabetes care technology provider.
	2023-02-22	-2.07 %
The stock of Dexcom(DXCM) goes down because their CGM portfolio is expanding and they are unveiling new clinical and real-world evidence that their CGM is effective at managing diabetes. Apple has a secret project underway to create a non-invasive continuous glucose monitor which could upend the diabetes-monitoring industry. Dexcom's announcement of the Dexcom G6 CGM system in Singapore for people with diabetes is a significant development. The launch of the system marks the first time Dexcom's CGM is available to people living with diabetes in Southeast Asia and with the recent opening of Dexcom's regional headquarters in Singapore, the company looks forward to bringing Dexcom CGM to additional markets in the region in the near future. Bloomberg News reports that Apple is progressing on its work to add a blood glucose monitor to its market-dominating Apple Watch, which could compete with Dexcom's line of CGMs.
	2023-02-21	-0.65 %
Dexcom has been in the news because the FDA approved their device to monitor blood sugar without pricking fingers. However, the stock price has gone down because some investors are worried that the device will not be profitable enough. The company released disappointing earnings which led to a stock price drop.
	2023-02-16	-2.42 %
The stock price of dexcom(DXCM) falls when analysts report that the company's revenue growth may not meet or beat expectations.
	2023-02-13	+0.33 %
DexCom is a leading developer and manufacturer of continuous glucose monitoring (CGM) devices, which help people monitor and manage their blood sugar levels. These devices are used by people with diabetes and other conditions, and could have widespread use in the future. The company is doing well, and its stock is currently going down after recent surge in COVID-19 cases. This could be an opportunity to buy the stock at a lower price. The Dexcom stock price goes up because it is a leader in the diabetes care industry. Dexcom(DXCM) stock goes up because Jim Cramer likes the company and thinks it will do well in the future. Dexcom(DXCM) is a company that makes devices that help monitor patients' blood sugar levels. Investors buy these devices because people with diabetes need to monitor their blood sugar levels regularly in order to control their diabetes. Dexcom(DXCM) pays no dividend, but the company has posted a total return to shareholders of 6.6% over the past 12 months and nearly 100% over the past three years.
	2023-02-10	+9.93 %
dexcom(DXCM) stock goes up because companies like cloudflare and google give it good news which drives the stock prices up. DexCom's latest quarterly results were better than expected, sending the company's stock prices up. CloudFlare is an up and coming company, IQVia Holdings is doing well and Dexcom is a medical device company.
	2023-02-09	-2.37 %
The stock goes down because analysts expect the company to earn a lower profit than it did in the past. The stock of Dexcom goes down when the company reports earnings, and analysts' expectations are higher than what Dexcom actually achieves.
	2023-02-08	+0.31 %
The integration with Dexcom will improve access to Dario's multi-chronic condition platform for more people living with diabetes.
	2023-02-07	+2.6 %
Dexcom(DXCM) stock goes up because the company announced that it is releasing its new Dexcom G7 CGM system. This system is more accurate and easy to use than other CGM systems, and it is trusted for use during pregnancy. This announcement is part of a broader awareness campaign to raise awareness for life-changing CGM technology.
	2023-02-03	+0.37 %
Vertex Pharmaceuticals and DexCom are two strong growth stocks that are poised for even better performance in the future.
	2023-02-02	+0.3 %
The Dexcom G6 rtCGM system uses a small, wearable sensor and transmitter to continuously monitor and send glucose levels wirelessly to a smart device* or receiver, giving patients real-time glucose data without the need to scan or routinely prick their finger†. This system has customizable alerts, including a predictive low glucose alert which can help patients take action to avoid potentially dangerous low blood sugar events (<3.1 mmol/L), and a function that allows patients to share their glucose data with up to 10 followers. The use of Dexcom rtCGM is proven to improve glycemic controli,ii and can
	2023-01-30	-1.15 %
The dexcom(DXCM) stock goes down because the stock market is down and dexcom is a part of the consumer staples sector which is also down.
	2023-01-24	-0.35 %
A company releases their financial reports which show that they are doing poorly.
	2023-01-20	+1.56 %
DexCom is a growth stock that is forecasted to grow its revenue by as much as 20% in the upcoming fiscal year. Dexcom, Inc. (DXCM) is a medical device company that has received FDA approval for its next-gen G7 product. The company produces a technology that helps manage diabetes.
	2023-01-17	+0.96 %
The article discusses how the inflation dragon has been slain, which has raised expectations for a normalized rate of inflation. This causes the stock market to rally and raise prices for goods and services.
	2023-01-13	+1.24 %
DexCom is a diabetes care giant that is expected to see strong growth in the near future. The company is in the process of executing the global launch of its latest generation of its CGM devices. This will boost its revenue by as much as 20%.
	2023-01-12	+0.92 %
The small UK trial suggests that artificial pancreas systems that improve blood sugar control in type 2 diabetes are coming closer to reality. Dexcom(DXCM) stock goes up because the company develops and manufactures devices that monitor blood glucose levels.
	2023-01-11	-4.26 %
The stock price of Dexcom(DXCM) goes down when there is bad news about their products or dealings.
	2023-01-10	+0.75 %
Dexcom has a dominant position in the cystic fibrosis treatment market.
	2023-01-09	-4.97 %
The company issued disappointing guidance for the fourth quarter and full year. The stock goes down because the market is pessimistic about the future of the economy and equities. Shares of Dexcom (DXCM) fell on Thursday after the company reported preliminary, unaudited revenue for the fourth quarter and fiscal year 2022 that were above expectations.
	2023-01-06	+3.7 %
Simply Wall St believes that investors should buy and hold high quality multi-year winners. And highest quality companies can see their share prices grow by huge amounts. DexCom, Inc. (DXCM) is an example of a high quality company that has seen its share price skyrocket over the last five years.
	2023-01-04	-0.35 %
The dexcom(DXCM) stock price goes down because the company is investing in new technologies and the market is expecting these technologies to be successful.
	2023-01-03	+1.32 %
Dexcom's CEO will be presenting at the J.P. Morgan Healthcare Conference on January 9, 2023. This gives shareholders the opportunity to hear the company's latest developments and plans for the future.
	2022-12-27	-1.4 %
third consecutive day of losses
	2022-12-20	+0.82 %
track record of revenue growth and profitability
	2022-12-16	-1.39 %

	2022-12-14	+1.61 %
trying to break out past a 123.46 buy point in a flat base and is just below the entry
	2022-12-09	-5.06 %

	2022-12-08	+4.04 %
after the U.S. Food and Drug Administration cleared its G7 continuous glucose monitor up-and-coming device makers such as the diabetes care company DexCom have yielded life-changing gains for shareholders clearance from the Food and Drug Administration for its next-generation continuous glucose monitoring system The maker of glucose monitoring systems for diabetes management saw its shares rise 4.6% after announcing the U.S. Food and Drug Administration has cleared its G7 device for people with all types of diabetes ages two years and older life-changing gains for shareholders
	2022-12-05	-1.31 %

	2022-12-01	+1.5 %
rising diagnoses of diabetes growing prevalence of diabetes
	2022-11-18	+0.96 %

	2022-11-15	+2.94 %
The stock's rise snapped a two-day losing streak
	2022-11-08	+0.02 %
investors appear to be increasingly bullish about DexCom continued success of its CGM devices and robust revenue growth paired with consistent profitability
	2022-11-07	+0.39 %
its prospective patient pool continues to grow
	2022-11-04	+2.02 %
growth potential
	2022-11-02	-2.6 %
nervous about adding the stock to their own portfolios third consecutive day of losses
	2022-10-28	+19.38 %
diabetes-care technology company announced its third-quarter results solid demand for its HIV and cancer therapies diabetes management systems the medical device maker posted better-than-expected financials for Q3 2022 after the medical device company beat earnings and revenue expectations for the third quarter
	2022-10-25	+2 %

	2022-10-19	-0.09 %
the stock has followed the general market movement
	2022-10-07	+7.28 %
Centers for Medicare and Medicaid Services updated a local coverage determination related to such devices ~10% in the pre-market trading Friday after the Centers for Medicare and Medicaid Services (SMC) issued a proposed local coverage determination related to continuous glucose monitoring devices
	2022-10-04	+7.05 %
international expansion

1
500 / page